Live · updated just now

LSD-based pill passes two big trials for anxiety and depression

Sunday, 8 November 2026 · Mental health & wellbeing · Full report · Evidence: Moderate

What was found

A single 100-microgram dose of DT120, a form of LSD (lysergide) given as a tablet that dissolves in the mouth, met its main goals in two late-stage trials 1. In generalized anxiety disorder, scores on a standard clinician-rated anxiety scale (HAM-A) fell by 11.6 points by week 12. That was 5.4 points more than with placebo. In this group, 43% responded and 14% reached remission, compared with 16% and 4% on placebo 1. In major depressive disorder, scores on a depression scale (MADRS) dropped 8.1 points more than placebo at week 6 and 7.3 points more at week 12. At week 6, 35% responded versus 7% on placebo, and 24% reached remission versus 3% 1. In both trials, clear improvements appeared within the first week. No serious side effects or signs of increased suicidal thinking were reported. Common mild-to-moderate effects included visual illusions, nausea, and euphoric mood on the dosing day, followed by headache 1.

Who it applies to

The anxiety trial enrolled adults with generalized anxiety disorder, with an average age of 42 and high starting anxiety scores. The depression trial enrolled adults with major depressive disorder, with an average age of 44 and a current episode lasting between 8 weeks and 24 months. Some participants had already tried other treatments. Everyone received the drug in a supervised clinical setting 1.

How strong the evidence is

Moderate.